Objective This study aims to investigate the expression of delta-like 1(DLKl) gene in the bone marrow cells of patients with myelodysplastic syndromes(MDS) and to explore its molecular characteristics for the early di...Objective This study aims to investigate the expression of delta-like 1(DLKl) gene in the bone marrow cells of patients with myelodysplastic syndromes(MDS) and to explore its molecular characteristics for the early diagnosis of MDS. Methods The expression of DLK1 mRNA in the bone marrow cells of cases with MDS,acute myeloid leukemia(AML),and normal control groups were measured by real-time polymerase chain reaction and were analyzed for clinical significance. Results Significantly higher expression of DLK1 mRNA was observed in the bone marrow cells of MDS patients(0.7342±0.3652) compared with the normal control group(0.4801±0.1759)(P<0.05).The expression of DLK1 mRNA had a positive correlation with the proportion of bone marrow blasts(r=0.467,P<0.05).Moreover,DLKl mRNA expression was significantly increased as MDS progressed (P<0.05).Patients with abnormal karyotypes exhibited significantly higher expression of DLKl mRNA(0.9007±0.4334) than those with normal karyotypes(0.6411±0.2630)(P<0.05).Subsequently,patients with highly expressed DLKl(>0.8) presented significantly higher malignant clone burden(0.4134±0.3999) than those with lower DLKl expression(<0.8),(0.1517±0.3109),(P<0.05). Conclusions The DLK1 gene was highly expressed in MDS patients,and was increased as MDS progressed.The expression of DLK1 mRNA was positively correlated with the proportion of the bone marrow blasts.A high expression of DLKl gene suggested a higher malignant clone burden of MDS.展开更多
Objective To investigate the expression of TET2 mRNA and protein in the bone marrow mononuclear cells(BMMNC) of patients with myelodysplastic syndrome(MDS) and its clinical significance. Methods The expression of TET2...Objective To investigate the expression of TET2 mRNA and protein in the bone marrow mononuclear cells(BMMNC) of patients with myelodysplastic syndrome(MDS) and its clinical significance. Methods The expression of TET2 mRNA and protein in bone marrow mononuclear cells(BMMNC) of 32 patients with MDS and 20 healthy donors was examined by qPCR and Western blot. Results The expression of TET2 mRNA in BMMNC was down-regulated in MDS patients compared with the donor group [(0.41±0.28)%vs.(1.07±0.56)%](P<0.001).Compared with lower expression group(TET2<0.4)[(6.53±6.17)%],patients with higher expression of TET2(≥0.4) presented significantly lower proportion of bone marrow blasts[(1.21±1.56)%](P<0.05).The expression of TET2 mRNA in BMMNC of MDS patients was inversely correlated with malignant clone burden(r=-0.398,P<0.05) and IPSS(r=-0.412, P<0.05).The expression of TET2 protein was down-regulated in MDS patients compared with that in the donor group. Conclusions The mRNA and protein expression of TET2 in BMMNC of MDS patients is decreased,which might be useful as an important parameter for the evaluation of MDS clone burden.展开更多
OBJECTIVE:To unmask the underlying mechanisms of Yisui granule(益髓颗粒,YSG)for the treatment of Myelodysplastic syndromes(MDS).METHODS:Our study used an SKM-1 mouse xenograft model of MDS to explore the anti-tumor po...OBJECTIVE:To unmask the underlying mechanisms of Yisui granule(益髓颗粒,YSG)for the treatment of Myelodysplastic syndromes(MDS).METHODS:Our study used an SKM-1 mouse xenograft model of MDS to explore the anti-tumor potential of YSG and its safety,assess its effect on overall survival(OS),and evaluate whether its mechanism is associated with the demethylation of the secreted frizzled related protein 5(s FRP5)gene and suppressing Wnt/β-catenin pathway.Bisulfite amplicon sequencing was applied to detect the level of methylation of the s FRP5 gene;western blotting,immunofluorescence staining,and real-time Polymerase Chain Reaction were performed to detect DNA methyltransferase 1(DNMT1),s FRP5,and other Wnt/β-catenin pathway-related m RNA and protein expression.RESULTS:The results showed that high-dosage YSG exerted an anti-tumor effect similar to that of decitabine,improved OS,and reduced long-term adverse effects in the long term.Mechanically,YSG reduced the expression of DNMT1 methyltransferase,decreased the methylation,and increased the expression of the Wnt/β-catenin pathway antagonist-s FRP5.Furthermore,components of the Wnt/β-catenin pathway,including Wnt3a,β-catenin,c-Myc,and cyclin D1,were down-regulated in response to YSG,suggesting that YSG could treat MDS by demethylating the s FRP5 gene and suppressing the Wnt/β-catenin pathway.CONCLUSIONS:Our findings demonstrated that YSG could be used alone or in combination with decitabine to improve outcomes in the MDS animal model,providing an alternative solution for treating MDS.展开更多
Background:The diagnosis of myelodysplastic syndrome (MDS),especially hypoplastic MDS,and MDS with low blast counts or normal karyotype may be problematic.This study characterized ID4 gene methylation in patients w...Background:The diagnosis of myelodysplastic syndrome (MDS),especially hypoplastic MDS,and MDS with low blast counts or normal karyotype may be problematic.This study characterized ID4 gene methylation in patients with MDS and aplastic anemia (AA).Methods:The methylation status ofID4 was analyzed by bisulfite sequencing polymerase chain reaction (PCR) and quantitative real-time methylation-specific PCR (MethyLight PCR) in 100 patients with MDS and 31 patients with AA.Results:The MDS group had a higher ID4 gene methylation positivity rate (22.22%) and higher methylation levels (0.21 [0-3.79]) than the AA group (P 〈 0.05).Furthermore,there were significant differences between the hypoplastic MDS and AA groups,the MDS with low blast count and the AA groups,and the MDS with normal karyotype and the AA groups.The combination of genetic and epigenetic markers was used in much more patients with MDS (62.5% [35/56]) than the use of genetic markers only (51.79% [29/56]).Conclusions:These results showed that the detection ofID4 methylation positivity rates and levels could be a useful biomarker for MDS diagnosis.展开更多
Objective To investigate expression of Evi 1 and MDS1 Evi 1 genes in myelodysplastic syndromes (MDS) and post MDS acute myeloid leukemia (post MDS AML), and its role in pathogenesis or progression of MDS and pos...Objective To investigate expression of Evi 1 and MDS1 Evi 1 genes in myelodysplastic syndromes (MDS) and post MDS acute myeloid leukemia (post MDS AML), and its role in pathogenesis or progression of MDS and post MDS AML Methods Expression of Evi 1 and MDS1 Evi 1 genes was examined in 31 MDS, 11 post MDS AML, and 34 de novo AML patients by a semi quantitative reverse transcription polymerase chain reaction (RT PCR) Results Evi 1 expression was not detected in bone marrow samples of 8 normal controls, but low MDS1 Evi 1 expression levels (MDS1 Evi 1/GAPDH<0 1) were detected in 3 of the 8 controls Evi 1 RNA was expressed in 1 of 8 RA, 8 of 13 RAEB and 6 of 9 RAEB T patients, and the percentage of Evi 1 expression in RAEB(T) patients was higher than that in RA (P<0 05) MDS1 Evi 1 expression was detected in 5 of 8 RA, 9 of 13 RAEB and 5 of 9 RAEB T patients, and MDS1 Evi 1 expression levels (MDS1 Evi 1/GAPDH>0 1) were markedly higher than those in the controls Evi 1 expression was gradually increased in 4 of 5 RAEB T patients with transformation from MDS to AML The percentages of Evi 1 and MDS1 Evi 1 expression in post MDS AML patients were significantly (P<0 01 and P<0 05 respectively) higher than those in de novo AML The colonies of hematopoietic progenitor cells were decreased in Evi 1 and MDS1 Evi 1 positive MDS patients as compared with those in Evi 1 and MDS1 Evi 1 negative patients Conclusion Abnormal expression of the Evi 1 gene and overexpression of MDS1 Evi 1 gene may play a role in the pathogenesis or progression of MDS and post MDS AML展开更多
Objective Based on our previous established cohort of myelodysplastic syndrome(MDS),we investigated the potential effect of beta-tubulin(TUBB)gene in the transformation of MDS into acute leukemia.Methods From our nest...Objective Based on our previous established cohort of myelodysplastic syndrome(MDS),we investigated the potential effect of beta-tubulin(TUBB)gene in the transformation of MDS into acute leukemia.Methods From our nested case-control study cohort of MDS patients,we chose 11 paired transformed and non-transformed展开更多
基金supported by National Natural Science Foundation of China(No.81170472)Chinese Medical Association Molecular Biology Clinical Application Research Special Funds(No.CAMB042010)Tianjin Application Bases and Advanced Technology Research Program(No.09JCYBJC11200)
文摘Objective This study aims to investigate the expression of delta-like 1(DLKl) gene in the bone marrow cells of patients with myelodysplastic syndromes(MDS) and to explore its molecular characteristics for the early diagnosis of MDS. Methods The expression of DLK1 mRNA in the bone marrow cells of cases with MDS,acute myeloid leukemia(AML),and normal control groups were measured by real-time polymerase chain reaction and were analyzed for clinical significance. Results Significantly higher expression of DLK1 mRNA was observed in the bone marrow cells of MDS patients(0.7342±0.3652) compared with the normal control group(0.4801±0.1759)(P<0.05).The expression of DLK1 mRNA had a positive correlation with the proportion of bone marrow blasts(r=0.467,P<0.05).Moreover,DLKl mRNA expression was significantly increased as MDS progressed (P<0.05).Patients with abnormal karyotypes exhibited significantly higher expression of DLKl mRNA(0.9007±0.4334) than those with normal karyotypes(0.6411±0.2630)(P<0.05).Subsequently,patients with highly expressed DLKl(>0.8) presented significantly higher malignant clone burden(0.4134±0.3999) than those with lower DLKl expression(<0.8),(0.1517±0.3109),(P<0.05). Conclusions The DLK1 gene was highly expressed in MDS patients,and was increased as MDS progressed.The expression of DLK1 mRNA was positively correlated with the proportion of the bone marrow blasts.A high expression of DLKl gene suggested a higher malignant clone burden of MDS.
基金supported by grants from the National Natural Science Foundation of China(No.30971286, 30971285,81170472)Chinese Medical Association of Molecular Biology Clinical Application Research Special Funds(No.CAMB042010)+1 种基金The"Eleventh Five-year Plan"National Science and Technology Support Plan(No. 2008BA161B00)Health Industry Research Special Project (No.201002024)
文摘Objective To investigate the expression of TET2 mRNA and protein in the bone marrow mononuclear cells(BMMNC) of patients with myelodysplastic syndrome(MDS) and its clinical significance. Methods The expression of TET2 mRNA and protein in bone marrow mononuclear cells(BMMNC) of 32 patients with MDS and 20 healthy donors was examined by qPCR and Western blot. Results The expression of TET2 mRNA in BMMNC was down-regulated in MDS patients compared with the donor group [(0.41±0.28)%vs.(1.07±0.56)%](P<0.001).Compared with lower expression group(TET2<0.4)[(6.53±6.17)%],patients with higher expression of TET2(≥0.4) presented significantly lower proportion of bone marrow blasts[(1.21±1.56)%](P<0.05).The expression of TET2 mRNA in BMMNC of MDS patients was inversely correlated with malignant clone burden(r=-0.398,P<0.05) and IPSS(r=-0.412, P<0.05).The expression of TET2 protein was down-regulated in MDS patients compared with that in the donor group. Conclusions The mRNA and protein expression of TET2 in BMMNC of MDS patients is decreased,which might be useful as an important parameter for the evaluation of MDS clone burden.
基金Clinical Translational Research of Beijing Municipal Science and Technology Commission,Administrative Commission of Zhongguancun Science Park-funded Project:Study on Mechanisms and Efficacy of Yisui granule Treating Low and Intermediate Risk of Myelodysplastic Syndromes via DNA Demethylation(No.Z211100002921018)National Natural Science Foundation of Chinafunded Projects:Study on Molecular Mechanisms of Yisui granule Treating Myelodysplastic Syndromes via Regulating DNA Methylation(No.81503575)+1 种基金Mechanism Study of Tea Polyphenols activating c GAS-STING Pathway to Inhibit Lung Adenocarcinoma Immune Escape based on Redox Balance(No.82172760)the Golden Bridge Project of Beijing Association for Science and Technology-funded Project:Study on Mechanisms of Yisui granule Treating Low and Intermediate Risk of Myelodysplastic Syndromes via DNA Demethylation(No.ZZ20059)。
文摘OBJECTIVE:To unmask the underlying mechanisms of Yisui granule(益髓颗粒,YSG)for the treatment of Myelodysplastic syndromes(MDS).METHODS:Our study used an SKM-1 mouse xenograft model of MDS to explore the anti-tumor potential of YSG and its safety,assess its effect on overall survival(OS),and evaluate whether its mechanism is associated with the demethylation of the secreted frizzled related protein 5(s FRP5)gene and suppressing Wnt/β-catenin pathway.Bisulfite amplicon sequencing was applied to detect the level of methylation of the s FRP5 gene;western blotting,immunofluorescence staining,and real-time Polymerase Chain Reaction were performed to detect DNA methyltransferase 1(DNMT1),s FRP5,and other Wnt/β-catenin pathway-related m RNA and protein expression.RESULTS:The results showed that high-dosage YSG exerted an anti-tumor effect similar to that of decitabine,improved OS,and reduced long-term adverse effects in the long term.Mechanically,YSG reduced the expression of DNMT1 methyltransferase,decreased the methylation,and increased the expression of the Wnt/β-catenin pathway antagonist-s FRP5.Furthermore,components of the Wnt/β-catenin pathway,including Wnt3a,β-catenin,c-Myc,and cyclin D1,were down-regulated in response to YSG,suggesting that YSG could treat MDS by demethylating the s FRP5 gene and suppressing the Wnt/β-catenin pathway.CONCLUSIONS:Our findings demonstrated that YSG could be used alone or in combination with decitabine to improve outcomes in the MDS animal model,providing an alternative solution for treating MDS.
基金This work was supported by grants from the National Basic Research Program of China (2005CB522400), National Natural Science Foundation of China (90919044, 30971297, and 81000221 ), and National Key Scientific Instrument and Equipment Development Projects (2012YQ03026107). ACKNOWLEDGMENTS We thank Xu-Feng Luo, Jing-Xin Li, Xiao-Ning Gao, Li-Ping Dou, Yuan-Yuan Xu, and Yi Ding for discussion and technical assistance.
文摘Background:The diagnosis of myelodysplastic syndrome (MDS),especially hypoplastic MDS,and MDS with low blast counts or normal karyotype may be problematic.This study characterized ID4 gene methylation in patients with MDS and aplastic anemia (AA).Methods:The methylation status ofID4 was analyzed by bisulfite sequencing polymerase chain reaction (PCR) and quantitative real-time methylation-specific PCR (MethyLight PCR) in 100 patients with MDS and 31 patients with AA.Results:The MDS group had a higher ID4 gene methylation positivity rate (22.22%) and higher methylation levels (0.21 [0-3.79]) than the AA group (P 〈 0.05).Furthermore,there were significant differences between the hypoplastic MDS and AA groups,the MDS with low blast count and the AA groups,and the MDS with normal karyotype and the AA groups.The combination of genetic and epigenetic markers was used in much more patients with MDS (62.5% [35/56]) than the use of genetic markers only (51.79% [29/56]).Conclusions:These results showed that the detection ofID4 methylation positivity rates and levels could be a useful biomarker for MDS diagnosis.
文摘Objective To investigate expression of Evi 1 and MDS1 Evi 1 genes in myelodysplastic syndromes (MDS) and post MDS acute myeloid leukemia (post MDS AML), and its role in pathogenesis or progression of MDS and post MDS AML Methods Expression of Evi 1 and MDS1 Evi 1 genes was examined in 31 MDS, 11 post MDS AML, and 34 de novo AML patients by a semi quantitative reverse transcription polymerase chain reaction (RT PCR) Results Evi 1 expression was not detected in bone marrow samples of 8 normal controls, but low MDS1 Evi 1 expression levels (MDS1 Evi 1/GAPDH<0 1) were detected in 3 of the 8 controls Evi 1 RNA was expressed in 1 of 8 RA, 8 of 13 RAEB and 6 of 9 RAEB T patients, and the percentage of Evi 1 expression in RAEB(T) patients was higher than that in RA (P<0 05) MDS1 Evi 1 expression was detected in 5 of 8 RA, 9 of 13 RAEB and 5 of 9 RAEB T patients, and MDS1 Evi 1 expression levels (MDS1 Evi 1/GAPDH>0 1) were markedly higher than those in the controls Evi 1 expression was gradually increased in 4 of 5 RAEB T patients with transformation from MDS to AML The percentages of Evi 1 and MDS1 Evi 1 expression in post MDS AML patients were significantly (P<0 01 and P<0 05 respectively) higher than those in de novo AML The colonies of hematopoietic progenitor cells were decreased in Evi 1 and MDS1 Evi 1 positive MDS patients as compared with those in Evi 1 and MDS1 Evi 1 negative patients Conclusion Abnormal expression of the Evi 1 gene and overexpression of MDS1 Evi 1 gene may play a role in the pathogenesis or progression of MDS and post MDS AML
文摘Objective Based on our previous established cohort of myelodysplastic syndrome(MDS),we investigated the potential effect of beta-tubulin(TUBB)gene in the transformation of MDS into acute leukemia.Methods From our nested case-control study cohort of MDS patients,we chose 11 paired transformed and non-transformed